{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:37Z","timestamp":1793352937773,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.020","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:20:07Z","timestamp":1787959207000},"page":"3824-3826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preserving expertise in vitamin K antagonists in the era of direct oral anticoagulants: avoiding therapeutic segregation"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2905-1073","authenticated-orcid":false,"given":"C\u00e9line","family":"Everard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.020_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.020_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4140\/TCP.n.2023.86","article-title":"A review of the safety and efficacy of apixaban in patients with severe renal impairment","volume":"38","author":"Ifeanyi","year":"2023","journal-title":"Sr Care Pharm"},{"key":"10.1016\/j.jtha.2026.08.020_bib7","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/B:THRO.0000011378.16223.e4","article-title":"The clinical thrombosis center and clinical thrombologist: a new U.S. health systems paradigm for the management of venous thromboembolic disease","volume":"15","author":"Spyropoulos","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.08.020_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01061909","article-title":"Management of anticoagulant therapy: the Dutch experience","volume":"2","author":"Rosendaal","year":"1996","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.08.020_bib10","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archinte.158.15.1641","article-title":"Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs","volume":"158","author":"Chiquette","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.08.020_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11239-019-02031-4","article-title":"Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project","volume":"49","author":"Bernstein","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.08.020_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12757","article-title":"A call to action for anticoagulation stewardship","volume":"6","author":"Burnett","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.020_bib14","article-title":"Core elements of anticoagulation stewardship programs","year":"2019","journal-title":"Newton: Anticoagulation Forum"},{"key":"10.1016\/j.jtha.2026.08.020_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1002617","article-title":"Effect of home testing of international normalized ratio on clinical events","volume":"363","author":"Matchar","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10757","article-title":"AI-assisted warfarin dose optimisation with CURATE.AI for clinical impact: retrospective data analysis","volume":"10","author":"Gan","year":"2025","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jtha.2026.08.020_bib17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/ph18101544","article-title":"Machine learning for warfarin therapy: a systematic review","volume":"18","author":"F\u00fcl\u00f6p","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtha.2026.08.020_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00228-026-03997-w","article-title":"Artificial intelligence and machine learning for precision warfarin dosing: a comprehensive narrative review","volume":"82","author":"Shamohammadi","year":"2026","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:44Z","timestamp":1793350904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626005453"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preserving expertise in vitamin K antagonists in the era of direct oral anticoagulants: avoiding therapeutic segregation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}